|
|
Volumn 15, Issue 9, 2014, Pages 908-910
|
|
Combined inhibition of BRAF and MEK in melanoma patients
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
B RAF KINASE;
B RAF KINASE INHIBITOR;
COBIMETINIB;
DABRAFENIB;
MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;
MITOGEN ACTIVATED PROTEIN KINASE KINASE 3;
TRAMETINIB;
VEMURAFENIB;
AZETIDINE DERIVATIVE;
GDC-0973;
INDOLE DERIVATIVE;
PIPERIDINE DERIVATIVE;
SULFONAMIDE;
ACNE;
ARTHRALGIA;
CENTRAL SEROUS RETINOPATHY;
DIARRHEA;
DRUG DOSE ESCALATION;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG INHIBITION;
DRUG POTENCY;
DRUG SAFETY;
DRUG TOLERABILITY;
FATIGUE;
FEVER;
HUMAN;
HYPERPROLIFERATIVE SKIN LESION;
MELANOMA;
MONOTHERAPY;
NAUSEA;
NOTE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHOTOSENSITIVITY;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
QUALITY OF LIFE;
RASH;
SIGNAL TRANSDUCTION;
SKIN CARCINOMA;
SKIN DEFECT;
SQUAMOUS CELL CARCINOMA;
DRUG EFFECTS;
FEMALE;
MALE;
SKIN NEOPLASMS;
AZETIDINES;
FEMALE;
HUMANS;
INDOLES;
MALE;
MELANOMA;
PIPERIDINES;
PROTO-ONCOGENE PROTEINS B-RAF;
SKIN NEOPLASMS;
SULFONAMIDES;
|
|
EID: 84905007559
PISSN: 14702045
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/S1470-2045(14)70331-6 Document Type: Note |
|
Times cited : (6)
|
|
References (11)
|
